ClinicalTrials.gg
CompletedNCT02121210SARIL-RA-ONEUpdated Jun 20, 2017Results posted

To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)

A Phase 3 interventional study of sarilumab SAR153191 (REGN88) in Rheumatoid Arthritis, sponsored by Sanofi. Completed at 28 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-20.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.

Enrollment
9th of 22
132 · median 88
Started
2014
with 1 other
Phase 3
9 of 22
1 open now
Registered
13th of 22
by date
Lead sponsor
14 of 22
Sanofi

Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 9th largest by enrollment, is one of 2 that started in 2014, is one of 9 in phase 3, and was the 13th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About sarilumab

sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing sarilumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the immunogenicity of sarilumab administered as monotherapy.

Secondary Objectives:

  • To evaluate the other safety aspects of sarilumab administered as monotherapy.
  • To assess the exposure of sarilumab administered as monotherapy.
Read the detailed description

Total study duration was up to 34 weeks: Up to 4-week screening period, 24-week open-label treatment phase, 6-week post-treatment observation. After completion of the treatment phase of this study, participants were eligible to enter a long term safety study (LTS11210 - SARIL-RA-EXTEND) for continuous treatment with sarilumab (SAR153191 [REGN88]).

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of rheumatoid arthritis (RA) ≥ 3 months.
  • Moderately to severely active rheumatoid arthritis.
  • Participants who per investigator judgment were incomplete responders to at least 12 weeks of an adequate dose of continuous treatment with or who were intolerant of one or a combination of non-biologic disease modifying anti-rheumatic drugs (DMARDs).

Exclusion criteria

Exclusion criteria:

  • Participants \< 18 years of age.
  • Past history of, or current, or inflammatory systemic or localized joint disease(s) other than RA.
  • History of juvenile idiopathic arthritis or arthritis onset prior to age 16.
  • Severe active systemic RA, including but not limited to vasculitis, pulmonary fibrosis, and/or Felty's syndrome.
  • Prior treatment with any biologic anti-interleukin 6 (IL-6) or IL-6 receptor (IL-6R) antagonist therapies.
  • Treatment with prednisone > 10 mg or equivalent per day, or change in dosage within 4 weeks prior to randomization.
  • New treatment with or dose-adjustment of on-going nonsteroidal anti-inflammatory drug (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors within 4 weeks prior to randomization, except for the use of low-dose acetylsalicylic acid for cardiovascular diseases.
  • Use of parenteral or intra-articular glucocorticoids injection within 4 weeks prior to randomization.
  • Prior treatment with a Janus kinase (JAK) inhibitor (tofacitinib).
  • New treatment or dose-adjustment to on-going medication for dyslipidemia, such as statin, within 6 weeks prior to randomization.
  • Participation in any clinical research study evaluating another drug or therapy within 5 half-lives or 60 days of first dose of study drug administration, whichever is longer.
  • Participants with a history of other than adequately-treated carcinoma in-situ of the cervix, non- squamous cell or basal cell carcinoma of the skin, within 5 years prior to the randomization visit. Non-malignant lymphoproliferative disorders are also excluded.
  • Participants with active tuberculosis or untreated latent tuberculosis infection.
  • Pregnant or breast feeding women.

The above information is not intended to contain all considerations relevant to a Participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    Sarilumab 150 mg q2w

    Sarilumab 150 mg subcutaneous (SC) injection every two weeks (q2w) for 24 weeks.

    Drug: sarilumab SAR153191 (REGN88)

  • Experimental
    Sarilumab 200 mg q2w

    Sarilumab 200 mg SC injection q2w for 24 weeks.

    Drug: sarilumab SAR153191 (REGN88)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Incidence of Antidrug Antibodies (ADA)

    ADA to sarilumab and anti-sarilumab neutralizing antibodies in serum samples were determined using a validated electrochemiluminescence immunoassay method. Percentage of participants with positive ADA during treatment emergent adverse event (TEAE) period (time from first dose of investigational medicinal product \[IMP\] to last dose of IMP + 60 days) was determined. Persistent ADA Response: treatment-emergent ADA detected at 2 or more consecutive sampling time points during the TEAE period, where the first and last ADA positive samples were separated by a period of at least 16 weeks or if the last measured sample was positive. ADA samples were collected prior to IMP administration at Week 0 (baseline), Week 2, 4, 12, 24 and 30.

    Time frame: From Baseline to Week 30 [End of study (EOS)]

Secondary outcomes

  1. Serum Sarilumab Concentration

    Trough Concentration (Ctrough).

    Time frame: Pre-dose at Week 0 (Baseline), 2, 4, 12, 16, 20, 24 and 30

07

Results

Posted Jun 20, 2017

Participant flow

The study was conducted at 27 centers in 7 countries. A total of 201 participants were screened between 03 June 2014 and 20 October 2014.

Participant flow — Overall Study
MilestoneSarilumab 150 mg q2wSarilumab 200 mg q2w
Started6567
Completed5858
Not completed79
Withdrew: Adverse event57
Withdrew: Lack of efficacy20
Withdrew: Other than specified above02

Outcome measures

PrimaryPercentage of Participants With Incidence of Antidrug Antibodies (ADA)

ADA to sarilumab and anti-sarilumab neutralizing antibodies in serum samples were determined using a validated electrochemiluminescence immunoassay method. Percentage of participants with positive ADA during treatment emergent adverse event (TEAE) period (time from first dose of investigational medicinal product \[IMP\] to last dose of IMP + 60 days) was determined. Persistent ADA Response: treatment-emergent ADA detected at 2 or more consecutive sampling time points during the TEAE period, where the first and last ADA positive samples were separated by a period of at least 16 weeks or if the last measured sample was positive. ADA samples were collected prior to IMP administration at Week 0 (baseline), Week 2, 4, 12, 24 and 30.

Time frame:
From Baseline to Week 30 [End of study (EOS)]
Reported as:
Number · Percentage of participants
Percentage of Participants With Incidence of Antidrug Antibodies (ADA)
Percentage of participantsSarilumab 150 mg q2wSarilumab 200 mg q2w
Overall positive24.618.2
Persistent positive12.36.1
Persistent neutralizing positive10.83.0
SecondarySerum Sarilumab Concentration

Trough Concentration (Ctrough).

Time frame:
Pre-dose at Week 0 (Baseline), 2, 4, 12, 16, 20, 24 and 30
Reported as:
Mean · ng/mL
Serum Sarilumab Concentration
ng/mLSarilumab 150 mg q2wSarilumab 200 mg q2w
Serum Sarilumab Concentration7350 ± 803017200 ± 15900

Adverse events

Collected over All adverse events (AEs) were collected from signature of the informed consent form up to the final visit (Week 30) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sarilumab 150mg q2w—1/65 (1.5%)16/65 (24.6%)
Sarilumab 200mg q2w—2/67 (3%)23/67 (34.3%)
Most frequent serious events
Most frequent serious events
EventSarilumab 150mg q2wSarilumab 200mg q2w
OsteoarthritisMusculoskeletal and connective tissue disorders1/650/67
NeutropeniaBlood and lymphatic system disorders0/651/67
LacerationInjury, poisoning and procedural complications0/651/67
Most frequent other events
Most frequent other events
EventSarilumab 150mg q2wSarilumab 200mg q2w
NeutropeniaBlood and lymphatic system disorders8/6511/67
Injection site erythemaGeneral disorders5/652/67
Upper respiratory tract infectionInfections and infestations3/654/67
Urinary tract infectionInfections and infestations2/654/67
HypertensionVascular disorders0/654/67

Baseline characteristics

Randomized population that included any participant who signed an informed consent and was allocated to a randomized treatment regardless of whether the treatment kit was used or not.

Age, Continuous
Age, Continuous(years)Sarilumab 150 mg q2wSarilumab 200 mg q2wTotal
Mean51.1 ± 12.753.6 ± 14.152.4 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)Sarilumab 150 mg q2wSarilumab 200 mg q2wTotal
Female4957106
Male161026
08

Study locations

28 sites
  • Investigational Site Number 840072
    Gilbert, Arizona 85234, United States
  • Investigational Site Number 840049
    Upland, California 91786, United States
  • Investigational Site Number 840220
    South Miami, Florida 33143, United States
  • Investigational Site Number 840230
    Elizabethtown, Kentucky 42701, United States
  • Investigational Site Number 840233
    Minot, North Dakota 58701, United States
  • Investigational Site Number 840127
    Oklahoma City, Oklahoma 73103, United States
  • Investigational Site Number 840011
    Tulsa, Oklahoma 74104, United States
  • Investigational Site Number 840009
    Duncansville, Pennsylvania 16635, United States
  • Investigational Site Number 840025
    Jackson, Tennessee 38305, United States
  • Investigational Site Number 840032
    Amarillo, Texas 79124, United States
  • Investigational Site Number 840074
    Mesquite, Texas 75150, United States
  • Investigational Site Number 840124
    Clarksburg, West Virginia 26301, United States
  • Investigational Site Number 840231
    Franklin, Wisconsin 53132, United States
  • Investigational Site Number 152002
    Santiago, 7501126, Chile
  • Investigational Site Number 203034
    Pardubice, 53002, Czechia
  • Investigational Site Number 203001
    Praha 2, 12850, Czechia
  • Investigational Site Number 203002
    Uherske Hradiste, 686 01, Czechia
  • Investigational Site Number 233010
    Tallinn, 10138, Estonia
  • Investigational Site Number 233002
    Tallinn, 13419, Estonia
  • Investigational Site Number 348014
    Budapest, 1027, Hungary
  • Investigational Site Number 348025
    Budapest, 1027, Hungary
  • Investigational Site Number 348021
    Esztergom, 2500, Hungary
  • Investigational Site Number 616018
    Poznan, 61-397, Poland
  • Investigational Site Number 616031
    Warszawa, 01-518, Poland
  • Investigational Site Number 616012
    Wroclaw, 50-044, Poland
  • Investigational Site Number 643006
    Kemerovo, 650000, Russian Federation
  • Investigational Site Number 643001
    Moscow, 115522, Russian Federation
  • Investigational Site Number 643016
    Ryazan, 390026, Russian Federation
09

References and documents

Publications

  • Wells AF, Parrino J, Mangan EK, Paccaly A, Lin Y, Xu C, Fan C, Graham NMH, van Hoogstraten H, Torri A. Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs. Rheumatol Ther. 2019 Sep;6(3):339-352. doi: 10.1007/s40744-019-0157-3. Epub 2019 May 14. PubMed 31090044 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 2 years 1 month after primary completion. A results delay was requested in Jan 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2014
First posted
Apr 23, 2014
Start
Jun 2014
Primary completionActual
May 2015
CompletionActual
May 2015
Results delay requested
Jan 6, 2016
Results first posted
Jun 20, 2017
Last update
Jun 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02121210
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 23, 2014
Start date
Jun 2014
Primary completion
May 2015
Completion
May 2015
Results posted
Jun 20, 2017
Last update
Jun 20, 2017

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarilumab

Start the discussion